Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Neuroendocrine Tumors × Carboplatin × Clear all

Phase

Status

Completed 3 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 72 Breast Neoplasms 34 Triple Negative Breast Neoplasms 24 Ovarian Neoplasms 20 Lung Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 17 Fallopian Tube Neoplasms 17 Small Cell Lung Carcinoma 15 Neoplasm Metastasis 11 Prostatic Neoplasms 10 Esophageal Neoplasms 10 Endometrial Neoplasms 9 Colorectal Neoplasms 9 Neoplasms 8 Uterine Cervical Neoplasms 7 Carcinoma 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Pancreatic Neoplasms 6 Oropharyngeal Neoplasms 6 Urinary Bladder Neoplasms 5 Laryngeal Neoplasms 5 Head and Neck Neoplasms 5 Stomach Neoplasms 4 Mouth Neoplasms 4 Melanoma 4 Lymphoma, Large B-Cell, Diffuse 4 Carcinoma, Ovarian Epithelial 4 Urothelial Cancer 3 Seminoma 3 Salivary Gland Neoplasms 3

Interventions

lutetium Lu 177 dotatate 11 Magnetic Resonance Spectroscopy 6 Specimen Handling 5 cabozantinib 4 Nivolumab 4 pembrolizumab 3 Everolimus 3 amino-acid, glucose, and electrolyte solution 2 X-Rays 2 Temozolomide 2 Phantoms, Imaging 2 Octreotide 2 Ipilimumab 2 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 toripalimab 1 tislelizumab 1 peposertib 1 pazopanib 1 lenvatinib 1 entrectinib 1 avelumab 1 Salts 1 Random Allocation 1 Radionuclide Imaging 1 Positron-Emission Tomography 1 Poly(ADP-ribose) Polymerase Inhibitors 1 Oxaliplatin 1 Lutetium-177 1 Leucovorin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06232564 2026-01-14

PELICAN

Imperial College London

Phase 2 Active not recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡